drugset / Trial / NCT00445523
Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Patients with metastatic renal cell cancer will be enrolled to receive either Trovax® alone or Trovax® plus Interferon Alfa. The study will try to determine whether the use of Trovax® will delay tumor progression.
Timeline
- Start
- 2006-05
- Primary completion
- 2008-01
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TroVax | Vaccine | — | Intramuscular |
| Subject | interferon alfa-2b | Protein / enzyme biologic | 5e+06 iu | Subcutaneous |